Philipp Erben

7.4k total citations
161 papers, 3.8k citations indexed

About

Philipp Erben is a scholar working on Surgery, Hematology and Genetics. According to data from OpenAlex, Philipp Erben has authored 161 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Surgery, 57 papers in Hematology and 52 papers in Genetics. Recurrent topics in Philipp Erben's work include Chronic Myeloid Leukemia Treatments (55 papers), Bladder and Urothelial Cancer Treatments (54 papers) and Eosinophilic Disorders and Syndromes (46 papers). Philipp Erben is often cited by papers focused on Chronic Myeloid Leukemia Treatments (55 papers), Bladder and Urothelial Cancer Treatments (54 papers) and Eosinophilic Disorders and Syndromes (46 papers). Philipp Erben collaborates with scholars based in Germany, United States and United Kingdom. Philipp Erben's co-authors include Andreas Hochhaus, Martin C. Müller, Thomas Ernst, Jörge E. Cortes, Susan Branford, Giuseppe Saglio, Dong‐Wook Kim, Nicholas C.P. Cross, Rüdiger Hehlmann and Andreas Reiter and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Philipp Erben

157 papers receiving 3.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philipp Erben Germany	32	2.0k	1.8k	1.5k	830	699	161	3.8k
Shu Tamura Japan	8	2.5k 1.3×	1.6k 0.9×	1.1k 0.8×	1.0k 1.2×	119 0.2×	11	3.7k
John Nicoll United States	18	1.9k 0.9×	1.4k 0.8×	919 0.6×	935 1.1×	94 0.1×	30	3.2k
Philip Beer United Kingdom	32	2.3k 1.1×	2.7k 1.5×	955 0.6×	2.4k 2.9×	141 0.2×	87	4.6k
Rebecca F. McClure United States	31	2.4k 1.2×	2.9k 1.6×	1.4k 1.0×	2.0k 2.4×	136 0.2×	64	4.5k
Diana Griffith United States	16	1.1k 0.6×	605 0.3×	663 0.4×	852 1.0×	1.4k 2.0×	22	5.1k
Raajit K. Rampal United States	30	1.6k 0.8×	1.6k 0.9×	632 0.4×	1.7k 2.1×	114 0.2×	178	3.3k
Ronald Paquette United States	33	3.2k 1.6×	2.4k 1.3×	1.1k 0.8×	1.5k 1.9×	69 0.1×	119	5.0k
Kensuke Usuki Japan	26	1.5k 0.7×	828 0.5×	235 0.2×	1.0k 1.2×	169 0.2×	160	3.1k
Cox Eb United States	8	1.3k 0.7×	1.2k 0.6×	668 0.4×	565 0.7×	129 0.2×	10	2.7k
Yaping Shou United States	25	1.8k 0.9×	1.5k 0.8×	826 0.6×	1.1k 1.3×	67 0.1×	68	3.1k

Countries citing papers authored by Philipp Erben

Since Specialization

Citations

This map shows the geographic impact of Philipp Erben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philipp Erben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philipp Erben more than expected).

Fields of papers citing papers by Philipp Erben

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philipp Erben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philipp Erben. The network helps show where Philipp Erben may publish in the future.

Co-authorship network of co-authors of Philipp Erben

This figure shows the co-authorship network connecting the top 25 collaborators of Philipp Erben. A scholar is included among the top collaborators of Philipp Erben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philipp Erben. Philipp Erben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmidt, Claudia, Manuel Neuberger, Philipp Erben, et al.. (2025). Loss of YTHDC1 m6A reading function promotes invasiveness in urothelial carcinoma of the bladder. Experimental & Molecular Medicine. 57(1). 118–130.

Breyer, Johannes, Markus Eckstein, Danijel Sikic, et al.. (2023). Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial). Scientific Reports. 13(1). 15437–15437. 4 indexed citations

Neuberger, Manuel, Martina Schmidt, Vitor Coutinho Carneiro, et al.. (2023). Reinvestigating the clinical relevance of the m6A writer METTL3 in urothelial carcinoma of the bladder. iScience. 26(8). 107300–107300. 4 indexed citations

Wirtz, Ralph M., Maximilian C. Kriegmair, Philipp Erben, et al.. (2021). KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Journal of Personalized Medicine. 11(6). 473–473. 12 indexed citations

Schmidt, Helena, Katja Nitschke, Cleo‐Aron Weis, et al.. (2021). RNA Expression of DNA Damage Response Genes in Muscle-Invasive Bladder Cancer: Influence on Outcome and Response to Adjuvant Cisplatin-Based Chemotherapy. International Journal of Molecular Sciences. 22(8). 4188–4188. 5 indexed citations

Nitschke, Katja, Jost von Hardenberg, Philipp Nuhn, et al.. (2020). Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer. International Journal of Molecular Sciences. 21(12). 4373–4373. 6 indexed citations

Breyer, Johannes, Manish Monga, Roman Mayr, et al.. (2020). 758P Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC). Annals of Oncology. 31. S587–S588. 1 indexed citations

Müller, Kilian J., Katja Nitschke, Philipp Erben, et al.. (2020). B-MYB—p53-related relevant regulator for the progression of clear cell renal cell carcinoma. Journal of Cancer Research and Clinical Oncology. 147(1). 129–138. 5 indexed citations

Nitschke, Katja, Philipp Erben, Cleo‐Aron Weis, et al.. (2019). Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5. World Journal of Urology. 38(3). 637–645. 15 indexed citations

10.

Worst, Thomas Stefan, Christopher Previti, Katja Nitschke, et al.. (2019). miR-10a-5p and miR-29b-3p as Extracellular Vesicle-Associated Prostate Cancer Detection Markers. Cancers. 12(1). 43–43. 58 indexed citations

11.

Wu, Sheng, Katja Nitschke, Cleo‐Aron Weis, et al.. (2019). ANLN and TLE2 in Muscle Invasive Bladder Cancer: A Functional and Clinical Evaluation Based on In Silico and In Vitro Data. Cancers. 11(12). 1840–1840. 17 indexed citations

12.

Hardenberg, Jost von, Sarah Hartmann, Katja Nitschke, et al.. (2018). Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation. Clinical Genitourinary Cancer. 17(2). 145–153.e5. 8 indexed citations

13.

Breyer, Johannes, Wolfgang Otto, Ralph M. Wirtz, et al.. (2016). ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. Urologia Internationalis. 98(3). 282–289. 27 indexed citations

14.

Wezel, Felix, Philipp Erben, Timo Gaiser, et al.. (2016). Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine. Urologia Internationalis. 100(1). 122–125. 16 indexed citations

15.

Burchert, Andreas, Martin C. Müller, Philippe Kostrewa, et al.. (2010). Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia. Journal of Clinical Oncology. 28(8). 1429–1435. 120 indexed citations

16.

Lierman, Els, Rikkert L. Snoeckx, Elizabeth H. Stover, et al.. (2010). Downstream effectors of FIP1L1-PDGFRA as targets for therapy in chronic eosinophilic leukemia. Haematologica. 95. 165–165. 1 indexed citations

17.

Hughes, Timothy P., Giuseppe Saglio, Susan Branford, et al.. (2009). Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. Journal of Clinical Oncology. 27(25). 4204–4210. 236 indexed citations

18.

Chase, Andrew, Thomas Ernst, Andreas Fiebig, et al.. (2009). TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals. Haematologica. 95(1). 20–26. 56 indexed citations

19.

Hochhaus, Andreas, Philipp Erben, Thomas Ernst, & Martin Mueller. (2007). Resistance to Targeted Therapy in Chronic Myelogenous Leukemia. Seminars in Hematology. 44(1 Suppl 1). 15–24. 64 indexed citations

20.

Metzgeroth, Georgia, Dietmar Dinter, Philipp Erben, et al.. (2006). Systemic mastocytosis simulating osseous metastatic disease. British Journal of Haematology. 136(1). 1–1. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact